Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Running

PREDICT THE DRUG Using ex vivo functional genomics as biomarker to predict the effectivity of Venetoclax in patients with acute leukemias

Coordinator
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbH, Germany
Runs
1 January 2024 to 30 June 2025
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101113342

What the project is doing

In the project's own words, from its summary on CORDIS.

For decades, oncologists treating cancer patients desire biomarkers that predict drug sensitivity on a patient individual level; unfortunately, the challenge remains unsolved until today. As treating clinicians are unable to identify the patients who benefit most and despite advanced multi-omics diagnostics, the majority of cancer patients are treated according to risk groups. As a result, patients receive inactive drugs without benefit, but adverse effects and European healthcare systems lose significant resources without gain.

During my ERC CoG work, we developed a completely new test principle which has the potential to bridge the gap. The group of “targeted” anticancer drugs causes tumor cells to die by inhibiting a single specific signalling molecule; we used the CRISPR/Cas9 mediated gene knockout to mimic the activity of such targeted drugs. In proof-of-principle work, we used patient-derived xenograft (PDX) leukemia models to show that the knockout of a target gene in vitro was able to predict which patient´s PDX model responded to treatment with the respective drug in vivo.

Here, we plan to optimize our test system by studying knockout of BCL-2 to predict sensitivity to the BCL-2 targeting drug Venetoclax. The planned work harbours the potential of a major breakthrough to solve a long-standing challenge in anti-cancer treatment, namely to predict which individual patient´s tumor responds to which targeted.

Topics

Who is involved

OrganisationCityCountryRole
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbHNeuherbergGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI